HSBC Global Research lowered its target price for JD Health (06618) to HK$149 from HK$154 and maintained its "buy" rating.
The research house said it lifts its top line estimate for FY21e by 4%, but lower its FY21e/22e/23e net profit estimates by 37%/27%/33% respectively, after factoring in the company's investment plans in the next three years.
全新節目《說說心理話》青少年不可以戀愛！？真實個案講述驚心動魄經歷► 即睇
